Table 3.
Univariate and multivariate analysis of nephrotoxicity risk factors of 92 solid organ transplant patients
| Variable | Univariate analysis |
Multivariate analysis, P; OR (95% CI) | ||
|---|---|---|---|---|
| Nephrotoxicity | No nephrotoxicity | P; OR (95% CIa) | ||
| Deceased donor, no. (%) | 22 (73.3) | 43 (69.4) | 0.69; 1.22 (0.46–3.21) | |
| Donor mean age (yr) | 42.5 | 42 | 0.87; 1.00 (0.97–1.04) | |
| Recipient mean age (yr) | 47.5 | 50 | 0.73; 1.01 (0.97–1.04) | |
| Previous induction, no. (%) | 19 (63.3) | 28 (45.2) | 0.10; 2.10 (0.86–5.14) | |
| Previous rejection, no. (%) | 12 (40) | 16 (25.8) | 0.17; 1.92 (0.76–4.84) | |
| Organ transplanted, no. (%) | ||||
| Kidney | 23 (76.7) | 54 (87.1) | 0.21; 0.49 (0.16–1.50) | |
| Kidney/pancreas | 2 (3.2) | 4 (13.3) | 0.08; 4.62 (0.80–26.8) | |
| Liver | 3 (10) | 5 (8.1) | 0.76; 1.27 (0.28–5.69) | |
| Nephrotoxic drug use 15 days before and/or during polymyxin administration, no. (%) | 29 (96.7) | 55 (88.7) | 0.23; 3.69 (0.43–31.5) | |
| Cyclosporine | 9 (30) | 17 (27.4) | 0.80; 1.13 (0.43–2.96) | |
| Tacrolimus | 10 (33.3) | 18 (29) | 0.87; 1.08 (0.42–2.80) | |
| Vancomycin | 24 (80) | 29 (46.8) | 0.004; 4.55 (1.63–12.7) | 0.07; 2.8 (0.9–8.68) |
| Amphotericin B | 3 (10) | 5 (8.1) | 0.76; 1.27 (0.28–5.69) | |
| Ganciclovir | 5 (16.7) | 11 (17.7) | 0.90; 0.93 (0.29–2.96) | |
| Mean daily polymyxin dose (IU)b | 931,667 | 917,742 | 0.88; 1.0 (1.0–1.0) | |
| Polymyxin use, mean time (days)b | 19.5 | 15.2 | 0.025; 1.06 (1.01–1.1) | 0.037; 1.06 (1.00–1.12) |
| Polymyxin infusion time < 12 h, no. (%)b | 10 (34.5) | 10 (16.4) | 0.058; 2.68 (0.97–7.46) | |
| Mean serum creatinine level before polymyxin (mg/dl) | 1.87 | 2.39 | 0.125; 0.74 (0.50–1.09) | |
| Type of infection, no. (%) | ||||
| UTI | 6 (20) | 32 (51.6) | 0.005; 0.23 (0.08–0.65) | 0.053; 0.32 (0.10–1.01) |
| SSI | 8 (26.7) | 8 (12.9) | 0.11; 2.46 (0.82–7.36) | |
| Pneumonia | 6 (20) | 9 (14.5) | 0.51; 1.47 (0.47–4.60) | |
| ICU, no. (%) | 15 (50) | 20 (32.3) | 0.10; 2.10 (0.86–5.12) | |
| SOFAc score | 7.4 | 9.15 | 0.29; 0.92 (0.80–1.07) | |
| Presence of shock, no. (%) | 6 (9.7) | 5 (16.7) | 0.34; 1.87 (0.52–6.69) | |
a
CI, confidence interval.
b
For these analyses, data were available for 90 patients receiving polymyxin B, excluding two patients receiving polymyxin E.
c
SOFA, sequential organ failure assessment.